EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
Crossref DOI link: https://doi.org/10.1007/s00280-014-2631-5
Published Online: 2014-11-25
Published Print: 2015-01
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Koo, Dong-Hoe
Kim, Kyu-pyo
Choi, Chang-Min
Lee, Dae-Ho
Lee, Jae Cheol
Lee, Jung-Shin
Jang, Se Jin
Kim, Sang-We
Text and Data Mining valid from 2014-11-25